PFIZER INC PFE
Terms unclear
Unclear — read the filing yourself
No closing date could be read from these filings. Nothing has been filed for this offer in over six months, so it is treated as closed — a tender offer cannot run that long. Check the filings below if you think otherwise.
amendment with no indexed original - the original may predate the collection window or may not mention odd lots
| Status | Closed (assumed) |
|---|---|
| Closing date | could not be read; last filing 2013-06-27 |
| How it is priced | — |
| Odd-lot threshold | Fewer than 100 shares |
| Must tender everything you hold | Yes |
| Must tick the odd-lot box on the form | Not stated |
How it finished
Everyone else24.1521%
| Expired | 2013-06-21 |
|---|---|
| Shares tendered | 1,674,974,996 |
| Shares accepted | 405,117,195 |
| Proration factor | 24.2% |
| Overall acceptance | 24.2% |
Where each of these comes from
Every line above was read out of the filing. Here is the wording it was read from, so you can check it.
must_tender_all = True...change Offer was oversubscribed, Pfizer accepted tendered shares of Pfizer common stock on a pro rata basis in proportion to the total number of shares tendered. Stockholders who owned fewer than 100 shares of Pfizer common stock, or an “odd-lot,” who validly tendered all of their shares, were not subject to proration if they requested such preferential treatment in accordance with the terms of the Exchange Offer. All shares validly tendered and not validly withdrawn by eligible odd-lot stockholders who requested not to be subject to proration have been accepted. The final proration factor of 24.1520516% was applied to a...
threshold = 100...in exchange for the 400,985,000 shares of Zoetis common stock owned by Pfizer. Because the Exchange Offer was oversubscribed, Pfizer accepted tendered shares of Pfizer common stock on a pro rata basis in proportion to the total number of shares tendered. Stockholders who owned fewer than 100 shares of Pfizer common stock, or an “odd-lot,” who validly tendered all of their shares, were not subject to proration if they requested such preferential treatment in accordance with the terms of the Exchange Offer. All shares validly tendered and not validly withdrawn by eligible odd-lot stockholders who requested not to be subject to prorat...
txn_type = TENDER_OFFERSC TO-I/A 1 d556202dsctoia.htm AMENDMENT NO.5 TO SCHEDULE TO Amendment No.5 to Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE TO (Amendment No. 5) (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 PFIZER INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, $0.05 Par Value (Title of Class of Securities) 717081103 (CUSIP Number of Class of Securities) Amy W. Schulman Executive Vice President and General Counsel Pfizer Inc...
accepted = 405117195...rk City time, on June 21, 2013. Under the terms of the Exchange Offer, 0.9898 shares of Zoetis common stock were exchanged for each share of Pfizer common stock accepted in the Exchange Offer. Pfizer accepted 405,117,195 shares of its common stock in exchange for the 400,985,000 shares of Zoetis common stock owned by Pfizer. Because the Exchange Offer was oversubscribed, Pfizer accepted tendered shares of Pfizer common stock on a pro rata basis in proportion to the total number of shares tendered. Stoc...
expired_on = 2013-06-21.... Item 4(a) of the Schedule TO, which incorporates by reference the information contained in the Exchange Offer, is hereby amended and supplemented by adding the following thereto: The Exchange Offer expired at 12:00 midnight, New York City time, on June 21, 2013. Under the terms of the Exchange Offer, 0.9898 shares of Zoetis common stock were exchanged for each share of Pfizer common stock accepted in the Exchange Offer. Pfizer accepted 405,117,195 shares of its common stock in exchange for the 400,985,000 shares of Zoetis common stock...
proration_pct = 24.1520516...dance with the terms of the Exchange Offer. All shares validly tendered and not validly withdrawn by eligible odd-lot stockholders who requested not to be subject to proration have been accepted. The final proration factor of 24.1520516% was applied to all other shares of Pfizer common stock that were validly tendered and not validly withdrawn to determine the number of such shares that have been accepted from each tendering stockholder. Based on the final count by the exchange agent, Computershare Trust Company...
tendered = 1674974996...g stockholder. Based on the final count by the exchange agent, Computershare Trust Company, N.A., the final results of the exchange offer are as follows: Total number of shares of Pfizer common stock validly tendered and not validly withdrawn 1,674,974,996 Shares tendered that were subject to proration 1,674,214,833 “Odd-lot” shares tendered that were not subject to proration 760,163 Total number of shares of Pfizer common stock accepted 405,117,195 On June 27, 2013, Pfizer issued a press release announcing the final results of the Excha...
The filings
| Filed | Form | Role | On EDGAR |
|---|---|---|---|
| 2013-06-27 | SC TO-I/A | amendment (governing) | View |